Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
Just published by the World Dementia Council and OHE is an analysis which sets out the dementia R&D landscape. This analysis was undertaken by OHE for…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are…
PriMHE Lecture: Relative Effectiveness and the Impact on Drug Development
28 May 2015
OHE’s Adrian Towse will give a lecture at the Medical University of Vienna on relative effectiveness and the impact on drug development.
OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs
12 May 2015
This post is the second of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015.
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the…
New Business Models for Antibiotics. What Can We Learn from Other Industries?
7 April 2015
The business model for antibiotics is broken. We looked at other industries facing conceptually similar challenges – particularly when the incentive for R&D is delinked from…
Medical Research: How Long Does it Take?
10 February 2015
It is surprisingly hard to measure how long medical research takes. A recently published study by OHE, Brunel and RAND Europe shows a better way to…
Benefiting Sooner from Medical Research
3 February 2015
Recently published study by OHE, Brunel University, RAND Europe and Kings College London analyses time lags in medical research and where to shorten them.